FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hedy Teppler

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Disorders

Living Beings

HIV-1

Co-author Network

Publications

TOP 3
Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Yazdan Yazdanpanah; Edwin DeJesus; Mark J DiNubile; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK.
Eduardo Gotuzzo; Chengxing Lu; Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Guillermo Prada; Winai Ratanasuwan; Graham Smith; Kim M Strohmaier; Hedy Teppler; Sanhita Bhanja
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
Edwin DeJesus; Mark J DiNubile; Adriano Lazzarin; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen; Jürgen K Rockstroh; Anthony J Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Jing Zhao
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hedy Teppler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Yazdan Yazdanpanah; Edwin DeJesus; Mark J DiNubile; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK.
Journal of acquired immune deficiency syndromes (1999) 2013;63(1):77-85.
2012: Eduardo Gotuzzo; Chengxing Lu; Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Guillermo Prada; Winai Ratanasuwan; Graham Smith; Kim M Strohmaier; Hedy Teppler; Sanhita Bhanja
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
Journal of acquired immune deficiency syndromes (1999) 2012;61(1):73-7.
2012: Edwin DeJesus; Mark J DiNubile; Adriano Lazzarin; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen; Jürgen K Rockstroh; Anthony J Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Jing Zhao
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV clinical trials 2012;13(4):228-32.
2011: Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Xia Xu; Jing Zhao; Edwin DeJesus; Mark J DiNubile; Adriano Lazzarin; Randi Leavitt; Jeffrey Lennox; Bach-Yen Nguyen
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(8):807-16.
2011: Jürgen K Rockstroh; Peter Sklar; Kim M Strohmaier; Hedy Teppler; Jing Zhao; Charlotte M Harvey; Randi Y Leavitt; Michael D Miller; Bach-Yen T Nguyen
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies.
AIDS (London, England) 2011;25(11):1365-9.
2011: Bach-Yen T Nguyen; Robin D Isaacs; Hedy Teppler; Randi Y Leavitt; Peter Sklar; Marian Iwamoto; Larissa A Wenning; Michael D Miller; Joshua Chen; Ramon Kemp; Wei Xu; Robert A Fromtling; Joseph P Vacca; Steven D Young; Michael Rowley; Michael W Lower; Keith M Gottesdiener; Daria J Hazuda
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Annals of the New York Academy of Sciences 2011;1222():83-9.
2011: Hedy Teppler; Deborah D Brown; Randi Y Leavitt; Peter Sklar; Hong Wan; Xia Xu; Fabio Lievano; Heidi P Lehman; T Christopher Mast; Bach-Yen T Nguyen
Long-term safety from the raltegravir clinical development program.
Current HIV research 2011;9(1):40-53.
2010: Jeffrey Lennox; Edwin Dejesus; Daniel S. Berger; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Jing Zhao; Hong Wan; Christopher L Gilbert; Hedy Teppler; Anthony Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Journal of acquired immune deficiency syndromes (1999) 2010;55(1):39-48.
2010: Roy T Steigbigel; David A Cooper; Hedy Teppler; Joseph J Eron; Jose M Gatell; Princy N Kumar; Jurgen K Rockstroh; Mauro Schechter; Christine Katlama; Martin Markowitz; Patrick Yeni; Mona R Loutfy; Adriano Lazzarin; Jeffrey Lennox; Bonaventura Clotet; Jing Zhao; Hong Wan; Rand R Rhodes; Kim M Strohmaier; Richard J Barnard; Robin D Isaacs; Bach-Yen Nguyen
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(4):605-12.
2009: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Havilland Campbell; Kim M Strohmaier; Hong Wan; Robert M Danovich; Hedy Teppler
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2009;52(3):350-6.
2009: Marian Iwamoto; Larissa A Wenning; Bach-Yen Nguyen; Hedy Teppler; Allison R Moreau; Rand R Rhodes; William D Hanley; Bo Jin; Charlotte M Harvey; Sheila A Breidinger; Neal Azrolan; H Frank Farmer; Robin D Isaacs; Jeffery A Chodakewitz; Julie A Stone; John A Wagner
Effects of omeprazole on plasma levels of raltegravir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(4):489-92.
2008: Larissa A Wenning; Evan J Friedman; James T Kost; Sheila A Breidinger; Jon E Stek; Kenneth C Lasseter; Keith M Gottesdiener; Joshua Chen; Hedy Teppler; John A Wagner; Julie A Stone; Marian Iwamoto
Lack of a significant drug interaction between raltegravir and tenofovir.
Antimicrobial agents and chemotherapy 2008;52(9):3253-8.
2008: David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2007: John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
AIDS (London, England) 2007;21(17):2315-21.
2007: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):125-33.
2006: Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):509-15.
2006: B E de Pauw; Carole A Sable; THOMAS WALSH; Robert J Lupinacci; M R Bourque; B A Wise; Bach-Yen Nguyen; Mark J DiNubile; Hedy Teppler
Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
Transplant infectious disease : an official journal of the Transplantation Society 2006;8(1):31-7.
2006: Robert Betts; Axel Glasmacher; Johan Maertens; Georg Maschmeyer; Jose A Vazquez; Hedy Teppler; Arlene Taylor; Robert J Lupinacci; Carole A Sable; Nicholas A Kartsonis
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Cancer 2006;106(2):466-73.
2005: Mark J DiNubile; Joseph W Chow; Vilas Satishchandran; Adam B Polis; Mary Motyl; Murray A Abramson; Hedy Teppler
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
Antimicrobial agents and chemotherapy 2005;49(8):3217-21.
2005: David L Paterson; Flávia Rossi; Fernando Baquero; Po-Ren Hsueh; Gail L Woods; Vilas Satishchandran; Theresa A Snyder; Charlotte M Harvey; Hedy Teppler; Mark J DiNubile; Joseph W Chow
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).
The Journal of antimicrobial chemotherapy 2005;55(6):965-73.
2004: THOMAS WALSH; Hedy Teppler; Gerald R Donowitz; Johan Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
The New England journal of medicine 2004;351(14):1391-402.
2004: Hedy Teppler; Richard M Gesser; Ian R Friedland; Gail L Woods; Anne R Meibohm; Gary A Herman; Goutam C Mistry; Robin Isaacs
Safety and tolerability of ertapenem.
The Journal of antimicrobial chemotherapy 2004;53 Suppl 2():ii75-81.
2004: Joseph S Solomkin; Hedy Teppler; Donald R Graham; Richard M Gesser; Anne R Meibohm; Subir Roy; Gail L Woods
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
The Journal of antimicrobial chemotherapy 2004;53 Suppl 2():ii51-7.
2004: Mary A Vogler; Hedy Teppler; Rebecca Gelman; Fred Valentine; Michael M Lederman; Roger J Pomerantz; Richard B Pollard; Deborah Weng Cherng; Charles J Gonzalez; Kathleen E Squires; Ian Frank; Donna Mildvan; Laura F Mahon; Barbara Schock
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Journal of acquired immune deficiency syndromes (1999) 2004;36(1):576-87.
2004: Hedy Teppler; Anne R Meibohm; Gail L Woods
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
Journal of chemotherapy (Florence, Italy) 2004;16(1):62-9.
2003: Eduardo Barboza; Joseph S Solomkin; Ellie J C Goldstein; Mario del Castillo; Ramón Alvarado; Aurelio Barboza; Hedy Teppler
[New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú 2003;23(3):192-8.
2003: Richard M Gesser; Kathleen McCarroll; Hedy Teppler; Gail L Woods
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
The Journal of antimicrobial chemotherapy 2003;51(5):1253-60.
2003: Joseph S Solomkin; Albert E Yellin; Ori D Rotstein; Nicolas V Christou; E Patchen Dellinger; Jose M Tellado; Osvaldo Malafaia; Alvaro Fernandez; Kyuran A Choe; Alexandra D Carides; Vilas Satishchandran; Hedy Teppler
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Annals of surgery 2003;237(2):235-45.
2003: Subir Roy; Iliana Higareda; Edith Angel-Muller; Mahmoud Ismail; Caren Hague; Ben Adeyi; Gail L Woods; Hedy Teppler
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Infectious diseases in obstetrics and gynecology 2003;11(1):27-37.
2002: Barbara A Pelak; Diane M Citron; Mary Motyl; Ellie J C Goldstein; Gail L Woods; Hedy Teppler
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
The Journal of antimicrobial chemotherapy 2002;50(5):735-41.
2002: Albert E Yellin; James M Hassett; Alvaro Fernandez; James Geib; Ben Adeyi; Gail L Woods; Hedy Teppler
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
International journal of antimicrobial agents 2002;20(3):165-73.
2002: Barbara A Pelak; Gail L Woods; Hedy Teppler; Ian R Friedland; Ken Bartizal; Mary Motyl
Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.
Journal of chemotherapy (Florence, Italy) 2002;14(3):227-33.
2002: David A Wohl; Francesca T Aweeka; John L Schmitz; Roger Pomerantz; Deborah Weng Cherng; John Spritzler; Lawrence Fox; David Simpson; Dawn Bell; M K Holohan; Steven Thomas; Wayne Robinson; Gilla Kaplan; Hedy Teppler
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
The Journal of infectious diseases 2002;185(9):1359-63.
2002: Hedy Teppler; Kathleen McCarroll; Richard M Gesser; Gail L Woods
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
Surgical infections 2002;3(4):337-49.
2002: Jose M Tellado; Gail L Woods; Richard M Gesser; Kathleen McCarroll; Hedy Teppler
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Surgical infections 2002;3(4):303-14.